EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Prostate‐specific antigen kinetics in Asian patients with metastatic castration‐sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis

Ding-Wei Ye, Hirotsugu Uemura iD, Byung Ha Chung iD, Hiroyoshi Suzuki iD, Suneel Mundle, Amitabha Bhaumik, Anildeep Singh, Simon Chowdhury, Neeraj Agarwal, Kim N Chi, Jian Huang

International Journal of Urology · 2025

DOI: 10.1111/iju.15615 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Urology, 2025. Verfasst von Ding-Wei Ye und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Thiohydantoins, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant, Androgen Antagonists. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Janssen Pharmaceutical Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

In the TITAN trial of patients with metastatic castration‐sensitive prostate cancer (mCSPC), deep and rapid prostate‐specific antigen (PSA) decline with apalutamide plus androgen deprivation therapy (ADT) was associated with longer overall survival (OS), radiographic progression‐free survival (rPFS), time to PSA progression (TTPP), and time to castration resistance (TTCR) compared with no decline (all p < 0.0001). This post hoc analysis evaluated PSA kinetics in the Asian subpopulation.

Methods

Data were analyzed for patients enrolled in China, Japan, and Korea and treated with apalutamide ( n = 111) or placebo ( n = 110) plus ADT. Examined were depth of PSA response, rates of PSA decline, and associations between a deep PSA response and clinical outcomes in apalutamide‐treated patients.

Results

Confirmed PSA response rates were higher with apalutamide than placebo: 73.9% versus 33.6% for PSA ≤0.2 ng/mL, 90.1% versus 58.2% for PSA reduction ≥50% [PSA50], and 74.8% versus 25.5% for PSA reduction ≥90% [PSA90]. Median (Q1; Q3) time to PSA ≤0.2 ng/mL, PSA50 and PSA90 response in the apalutamide group was 1.9 (1.0; 3.7), 1.0 (1.0; 1.0), and 1.8 (1.0; 1.9) months, respectively. PSA responses with apalutamide or placebo were consistent irrespective of high‐ or low‐volume disease. Achievement of confirmed PSA ≤0.2 ng/mL or PSA90 response with apalutamide at landmark 3 months was associated with significantly (nominal p ‐values) longer OS (hazard ratio: 0.23; p = 0.0009), TTPP (0.16; p = 0.0001), TTCR (0.20; p < 0.0001), and time to progression on first subsequent therapy or death (0.19; p < 0.0001) compared with no decline.

Conclusion

PSA kinetics have applications for early prognostic evaluation in Asian patients with mCSPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiohydantoinsProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantAndrogen AntagonistsHumansMaleAgedMiddle AgedProgression-Free SurvivalDouble-Blind MethodAsian PeopleChinaJapanTreatment OutcomeDisease ProgressionAndrogen Receptor AntagonistsRepublic of KoreaKallikreins

Stichwörter der Autor:innen

Asiaapalutamidemetastatic castration‐sensitive prostate cancerpost hoc analysisprostate‐specific antigen kinetics

Substanzen

ThiohydantoinsapalutamideProstate-Specific AntigenAndrogen AntagonistsAndrogen Receptor AntagonistsKLK3 protein, humanKallikreins

Autor:innen und Institutionen

  • Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Urology, Kindai University Hospital, Osaka-Sayama, Japan.
  • Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Urology, Toho University Sakura Medical Center, Chiba, Japan.
  • Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, New Jersey, USA.
  • Research & Development, Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, New Jersey, USA.

ORCID-Profile: Hirotsugu Uemura, Byung Ha Chung, Hiroyoshi Suzuki

Förderung

  • Janssen Pharmaceutical Ltd

Zitieren

APA

Ye, D. W., Uemura, H., Chung, B. H., Suzuki, H., Mundle, S., Bhaumik, A., Singh, A., Chowdhury, S., Agarwal, N., Chi, K. N., & Huang, J. (2025). Prostate‐specific antigen kinetics in Asian patients with metastatic castration‐sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis. International Journal of Urology. https://doi.org/10.1111/iju.15615

Vancouver

Ye DW, Uemura H, Chung BH, Suzuki H, Mundle S, Bhaumik A, et al. Prostate‐specific antigen kinetics in Asian patients with metastatic castration‐sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis. International Journal of Urology. 2025. doi:10.1111/iju.15615

BibTeX
@article{Ye2025,
  author = {Ye, Ding-Wei and Uemura, Hirotsugu and Chung, Byung Ha and Suzuki, Hiroyoshi and Mundle, Suneel and Bhaumik, Amitabha and Singh, Anildeep and Chowdhury, Simon and Agarwal, Neeraj and Chi, Kim N and Huang, Jian},
  title = {Prostate‐specific antigen kinetics in Asian patients with metastatic castration‐sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis},
  journal = {International Journal of Urology},
  year = {2025},
  doi = {10.1111/iju.15615}
}
Kostenlos starten →